Akero
Cathy Tamura has extensive work experience in the field of device development and engineering. Cathy currently holds the position of Senior Director of Device Development and Engineering at Akero Therapeutics since July 2023. Prior to this role, they worked as the Director of Device Development and Engineering at Akero Therapeutics from May 2022 to July 2023. Previously, they were a Principal Engineer at Amgen from January 2007 to May 2022. Cathy also worked as a Quality Engineer at Edwards Lifesciences from June 2002 to November 2006. Earlier in their career, they held the position of Engineer at Fluor Daniel from December 1992 to July 2001 and at Komag from 1985 to 1987.
Cathy Tamura holds a Master of Science degree in Materials Science, which they obtained from UCLA in the years 1987 to 1989. Prior to that, they graduated from UCLA with a Bachelor of Science degree in Chemical Engineering from 1980 to 1984.
This person is not in any offices
Akero
1 followers
Akero Therapeutics is a clinical-stage cardio-metabolic company developing transformational treatments for non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. Akero's lead product candidate, efruxifermin (EFX), an engineered Fc-FGF21 fusion protein, is currently being evaluated in a Phase 2b clinical trial as a potential treatment for NASH.